Welcome to the KIM Laboratory!
"More of the Right Cells
for Better Translational Medicine"
The KIM LABORATORY is working on bioprocessing expansion of cancer stem cells to better assist translational medicine. Cancer stem cells (CSCs) are considered the stem cell-like pluripotent cancer cells that cause relapse in patients even after the most rigorous treatment. Pharmaceutical companies, however, typically use several decades-old cancer cell lines during their drug development because, among many reasons, (1) CSCs are hard to acquire and (2) are limited in number. It is becoming increasingly recognized, however, drug development must be based on CSCs to develop better drugs that target the "real culprit" in tumors. Therefore, our work aims to bridge the oncologists with the engineers by developing large scale quantities of CSCs using engineering principles and systems biology tools (e.g. proteomics) for the mass production of CSCs from primary patient tissues and cell culture. By doing so, we hope to assist in the drug development by providing a more relevant and closer-to-clinic resource of cancer cells.
Note: The views, opinions, and conclusions expressed in these pages are those of the author or organization and not necessarily those of The University of Alabama or its officers and trustees. The content of this page has not been reviewed or approved by the University of Alabama, and the author or organization is solely responsible for its content.
Last updated: 12-3-2014